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OBJECTIVE—Carbohydrate-responsive element-binding pro-
tein (ChREBP) is a transcription factor that has been shown to
regulate carbohydrate metabolism in the liver and pancreatic
-cells in response to elevated glucose concentrations. Because
few genes have been identiﬁed so far as bona ﬁde ChREBP-target
genes, we have performed a genome-wide analysis of the
ChREBP transcriptome in pancreatic -cells.
RESEARCH DESIGN AND METHODS—Chromatin immuno-
precipitation and high-density oligonucleotide tiling arrays
(ChIP-chip; Agilent Technologies) using MIN6 pancreatic -cell
extracts were performed together with transcriptional and other
analysis using standard techniques.
RESULTS—One of the genes identiﬁed by ChIP-chip and linked
to glucose sensing and insulin secretion was aryl hydrocarbon
receptor nuclear translocator (ARNT)/hypoxia-inducible fac-
tor-1 (HIF-1), a transcription factor implicated in altered gene
expression and pancreatic-islet dysfunction in type 2 diabetes.
We ﬁrst conﬁrmed that elevated glucose concentrations de-
creased ARNT/HIF-1 levels in INS-1 (832/13) cells and primary
mouse islets. Demonstrating a role for ChREBP in ARNT gene
regulation, ChREBP silencing increased ARNT mRNA levels in
INS-1 (832/13) cells, and ChREBP overexpression decreased
ARNT mRNA in INS-1 (832/13) cells and primary mouse islets.
We demonstrated that ChREBP and Max-like protein X (MLX)
bind on the ARNT/HIF-1 promoter on the proximal region that
also confers the negative glucose responsiveness.
CONCLUSIONS—These results demonstrate that ChREBP acts
as a novel repressor of the ARNT/HIF-1 gene and might
contribute to -cell dysfunction induced by glucotoxicity.
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ancreatic -cell dysfunction or loss is the hall-
mark of all forms of diabetes (1,2). Transcription
factors have proven to be critical for the mainte-
nance of normal -cell function, and mutations in
many of these, including pancreatic duodenum ho-
meobox-1 (PDX1) (3) and the hepatocyte nuclear factors
HNF1 (4) and HNF4 (5) lead to monogenic forms of
inherited type 2 diabetes (6), whereas polymorphisms in
others, notably T-cell factor 7-like 2 (TCF7L2), are associ-
ated with more common forms of the disease (7).
Recently, a transcription factor termed aryl hydrocar-
bon receptor nuclear translocator (ARNT), or hypoxia-
inducible factor-1 (HIF-1), has emerged as a potentially
important player in the pathogenesis of pancreatic -cell
dysfunction and type 2 diabetes in humans (8). ARNT/
HIF-1 is a member of the basic helix-loop-helix (HLH)
Per/AhR/ARNT/Sim (PAS) family of transcription factors
and binds DNA as an obligate heterodimer with the
oxygen-sensitive HIF-1, HIF-2, or aryl hydrocarbon re-
ceptor (AhR). When mRNA levels were compared in
human pancreatic islets of Langerhans isolated from ﬁve
type 2 diabetic donors and seven nondiabetic donors by
oligonucleotide microarrays and real-time PCR, an 82%
reduction in the expression of the ARNT/HIF-1 gene was
observed in islets from type 2 diabetic donors. Conﬁrming
a role for ARNT/HIF-1 in -cell function, -cell–speciﬁc
ARNT/HIF-1 gene knockout in mice, or ARNT/HIF-1
silencing in MIN6 cells, led to defects in glucose-stimu-
lated insulin secretion (GSIS) and alterations in islet gene
expression comparable to those observed in human type 2
islets (8).
Carbohydrate-responsive element-binding protein (ChREBP)
(9) (also termed MondoB or Williams-Beuren syndrome
critical region gene 14 [WBSCR14]) (10) is a transcription
factor that regulates de novo lipogenesis in the liver in
response to elevated glucose concentrations (11). It is a
member of the basic HLH (bHLH) family and transactivates
glucose-responsive genes by binding DNA on carbohydrate
response element (ChoRE), as a heterodimer with Max-like
protein X (MLX) (12). In addition to its lipogenic role in the
liver, we have recently shown (13) that, in clonal pancreatic
-cells, 1) ChREBP mRNA levels are increased in response to
elevated glucose concentrations; 2) ChREBP translocates to
the nucleus in response to high glucose; 3) ChREBP directly
binds to the promoters of lipogenic genes fatty acid synthase
(FAS) and L-type pyruvate kinase (L-PK) in a glucose- and
calcium-dependent, but insulin-independent, manner in in-
tact cells; and 4) ChREBP silencing by small-interfering RNA
(siRNA) improves GSIS (13).
To identify other genes directly regulated by ChREBP in
the -cell, we performed a genome-wide analysis of the
ChREBP transcriptome using chromatin immunoprecipi-
tation and high-density oligonucleotide tiling arrays (ChIP-
on-chip; Agilent Technologies) in MIN6 cells. ARNT/
HIF-1 fell within the statistical cutoff and was considered
positive for ChREBP binding. Consequently, we demon-
strate that ChREBP directly binds to ARNT/HIF-1 pro-
moter in a glucose-dependent manner in clonal MIN6 and
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gene expression in pancreatic islet -cells.
These results suggest that ChREBP, in addition to being
a critical regulator of lipogenic genes in the liver and
pancreatic -cell, may also play a role in the development
of -cell failure and type 2 diabetes through alteration of
ARNT/HIF-1 gene expression.
RESEARCH DESIGN AND METHODS
Reagents. The Silencer siRNA construction kit was from Ambion (Hunting-
don, U.K.). Primers for siRNA construction and PCR were from MWG Biotech
(Milton Keynes, U.K.). TransIT-TKO transfection reagent was from Mirrus
(Madison, WI). The rat insulin radioimmunoassay kit was from Linco (St.
Charles, MO). Tissue culture reagents were from Sigma-Aldrich (Dorset, U.K.)
or Invitrogen (Paisley, U.K.). Lipofectamine 2000 and SYBR Green platinum
were from Invitrogen (Paisley, U.K.). Collagenase from C. histolyticum was
obtained from Serva Electrophoresis (Heidelberg, Germany). Anti-ChREBP
antibody was described by da Silva Xavier et al. (13). Mouse monoclonal
anti-hemaglutinin (HA) antibody was provided by Anindiya Roy (Cancer
Research U.K.). Other reagents were from Sigma or Fisher.
Plasmids, adenoviruses, and SiRNA generation. Plasmid pChREBP was
described (13). Plasmid bearing HA-tagged MLX cDNA was provided by Dr H.
Towle (University of Minnesota). Plasmid pARNT-2369.LucFF was generated
by PCR using MIN6 genomic DNA, AccuPrime TaqDNA Polymerase High
Fidelity (Invitrogen), and the following primers: forward, 5-cgcg GAG CTC
CAC AAG CTA AGA TCA TCT GAG AGG (SacI site underlined) and reverse,
5-cgcg CTC GAG GTT ACT TAC TAG GCA TCA GGG GAA (XhoI site
underlined). The resulting 2,662-bp fragment was subcloned into pCR2.1 by
TA cloning, digested by SacI, and subcloned into pGL3basic (Promega) at the
SacI site. Plasmids pARNT-1028.LucFF, pARNT-630.LucFF, and pARNT-1028-
769.LucFF were generated by digesting pARNT-2369.LucFF with BglII, KpnI,
and SpeI, respectively, gel puriﬁcation, and self-ligation. Plasmids pARNT-
1028[-443TA;-442_-402del].LucFF and pARNT-630[-440_-402del].LucFF were
generated by PCR using plasmids pARNT-1028.LucFF and pARNT-630.LucFF as
templates, respectively; Phusion Hot Start High-Fidelity DNA Polymerase
(Finnzymes); and the following primers: forward, 5- TTCTCTTTGCATT
TCACTGACG and reverse, 5- TCATCAGCATATGCTTCCTACAGAC. The re-
sulting PCR products were gel puriﬁed, phosphorylated using T4 kinase and
forward buffer (Invitrogen), and self-ligated. The differences in the sequences
of the resulting deletion mutants is probably because the primers used were
not PAGE puriﬁed. The E-boxes point mutations in pARNT-1028.LucFF and
pARNT-630.LucFF plasmids were introduced using a QuikChange Site-Di-
rected Mutagenesis Kit (Stratagene). Primer sequences for each mutant are
available on demand. pLPK-183.LucFF has been described previously (14).
pRL-CMV was from Promega. Adenovirus-encoding ChREBP was generated
by subcloning ChREBP cDNA into pAdTrackCMV using NotI-XbaI sites and
then ampliﬁed according to He et al. (15) and Ainscow and Rutter (16).
Adenovirus encoding GFP was described by Leclerc et al. (17). All constructs
were veriﬁed by DNA sequencing. SiRNAs were generated as described by da
Silva Xavier et al. (13) using The Silencer siRNA construction kit from Ambion
and the following primers (T7 underlined): rat ChREBP, 508 AAACCTGAG
GCTGTTGTCTTCCTGTCTC 527; scrambled, AAGGCTGTTTCACCTGAGTT
CCTGTCTC.
Islet isolation and culture. Male CD1 mice (12–13 weeks old) were killed by
cervical dislocation, and collagenase (1.0 mg/ml in Hanks’ balanced salt
solution) was injected into the pancreatic duct (5.0 ml/mouse). The distended
pancreata were then incubated in a shaking water bath at 37°C in 1.0 mg/ml
collagenase in Hanks’ balanced salt solution for 10 min, and the islets were
recovered using Histopaque gradient solutions (3 ml of 1.119 g/l; 3 ml of 1.083
g/l; 3 ml of 1.077 g/l). After centrifugation for 20 min at 2,500g, islets were
removed from the top layer and washed once with RPMI 1640. Mouse islets
were maintained in RPMI 1640 medium supplemented with 10% heat-inacti-
vated FCS plus antibiotics and incubated in a humidiﬁed atmosphere at 37°C
with 5% CO2. Infection of islets with adenoviruses was performed at a
multiplicity of infection of 100, and islets of no greater than 150 m diameter
were used to ensure infection of 30–50% of cells within each islet (18).
Measurements of insulin secretion were performed 48 h after infection.
Cell culture and transfection. MIN6 -cells (19) were used between
passages 19 and 30 and grown in Dulbecco’s modiﬁed Eagle’s medium
containing 25 mmol/l glucose and supplemented with 15% (vol/vol) heat-
inactivated FCS, 4 mmol/l L-glutamine, 25 mol/l -mercaptoethanol, 100
IU/ml penicillin, and 100 g/ml streptomycin in a humidiﬁed atmosphere at
37°C with 5% CO2 unless speciﬁed otherwise. INS-1 (832/13) -cells (20) were
cultured in RPMI 1640 containing 11 mmol/l glucose, 10% (vol/vol) FCS, 4
mmol/l L-glutamine, 100 IU/ml penicillin, 100 g/ml streptomycin, 10 mmol/l
HEPES, 1 mmol/l sodium pyruvate, 0.05 mmol/l -mercaptoethanol, or as
indicated. HEK293 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% (vol/vol) heat-inactivated FCS, 25 mmol/l glucose, 2 mmol/l
glutamine, 100 IU/ml penicillin, and 100 g/ml streptomycin. INS1 (832/13)
cells were transfected using Lipofectamine 2000 and Opti-Mem, according to
the manufacturer’s instructions, whereas HEK293 cells were transfected using
the calcium phosphate method, pH 7.12 (21).
Chromatin immunoprecipitation assay and ChIP-on-chip. Chromatin
immunoprecipitation was performed as described by da Silva Xavier et al.
(13). Brieﬂy, MIN6  or INS-1(832/13) cells were cultured in medium contain-
ing 3 mmol/l glucose for 16 h before stimulation with medium containing 3 or
30 mmol/l [20 mmol/l for INS-1(832/13)] glucose for 20 h before cross-linking
with 1% formaldehyde and sonication to obtain fragments of chromatin 1 kb.
DNA-protein complexes were immunoprecipitated with antibodies against
ChREBP or HA, followed by digestion with proteinase K (Boehringer Mann-
heim). The resulting DNA was extracted using phenol-chloroform and precip-
itated with ethanol. The mouse ARNT/HIF-1 promoter from 530 to 249 bp
was ampliﬁed using the following primers: 5-TGCTGATGAGCCCAC
TAAGA-3 and 5-ATAGAGGCCGGGCTAGTGAC-3. The mouse ARNT/HIF-1
promoter from 1,059 bp to 759 bp and 392 bp to 94 bp was ampliﬁed
using the following primer pairs: 5-GTCTTCAAACACACCAGACGA-3 and
5-GTGAGGTGTCCTATGTCAC-3;5 -CAGAAAGGACTGACAAGTGC-3 and
5-GCTGGCAGAGGGTTAAAAG-3, respectively. The sequence of the mouse
L-PK primers are given in the study by da Silva Xavier et al. (13). The rat
ARNT/HIF-1 promoter from 197 to 609 bp was ampliﬁed using the
following primers: 5-TTGCCTAGGAAGCACAAGG-3 and 5-AGCCTCCC
TGGGAAAACTGACC-3 and the rat ARNT/HIF-1 promoter 1,001 to 1,300
bp was ampliﬁed using the following primers: 5-GTCAGTCTAGGCTACTT
GAG-3 and 5-GGGCTAGTGGTGCATACCTTTAATC-3. The rat L-PK pro-
moter from 129 to 392 bp was ampliﬁed using the following primers:
5-AAAGTCTGCCTTAAGTGGGGC-3 and 5-TCCACCTTCCCTCCACCCA-3.
ChIP-on-chip was carried out using Agilent high-density oligonucleotide tiling
arrays (Agilent Technologies, Cheshire, U.K.) according to the manufacturer’s
protocol. The antibody-enriched DNA was blunt-ended and ligated to speciﬁc
linker and ampliﬁed using a two-stage PCR protocol. Fluorescence dyes Cy3
(3 mmol/l glucose) and Cy5 (30 mmol/l glucose) were used to label the
antibody-enriched DNA. The DNA was hybridized onto microarray slides for
up to 40 h at 40°C. The slides were washed, and the data were analyzed by
high-resolution scanning and Agilent ChIP Analytics software. To detect
signiﬁcant binding events, a minimum cutoff P value of 0.001 was used.
RNA isolation and quantitative real-time PCR. Primary mouse pancreatic
islets were treated for 24 h with ChREBP or null adenovirus in culture medium
containing 11 mmol/l glucose and then incubated for 16 h at 3 mmol/l glucose and
ﬁnally for 20 h at either 3 or 17 mmol/l glucose as indicated. Levels of mRNA
encoding the indicated genes were determined by quantitative real-time RT-PCR
and were normalized compared with cyclophillin mRNA as described by da Silva
Xavier et al. (22). Results are expressed as the fold change over control (null, 3
mmol/l glucose) and presented as the means  SE.
Insulin secretion and assay. After adenoviral infection (48 h), islets were
incubated for 60 min in a shaking water bath at 37°C in 1 ml Krebs-Ringer
bicarbonate HEPES buffer: 125 mmol/l NaCl, 3.5 mmol/l KCl, 1.5 mmol/l CaCl2,
0.5 mmol/l MgSO4, 0.5 mmol/l NaH2PO4, 2.0 mmol/l NaHCO3, 10 mmol/l
HEPES) supplemented with 3 mmol/l glucose/0.1% (wt/vol) BSA, equilibrated
with a mixture of 95% O2/5% CO2, pH 7.4. The islets were then separated into
four groups of six islets per condition and incubated for 30 min in 1.0 ml
Krebs-Ringer bicarbonate HEPES buffer as above, containing either 3 or 17
mmol/l glucose. Total insulin extracted from the islets in acidiﬁed ethanol was
carried out as described previously (17). Insulin was measured by radioim-
munoassay (Linco Research, St. Charles, MO).
Luciferase assays. Dual-Luciferase Reporter Assay System (Promega) was
used according to the manufacturer’s instructions.
DNA-protein interactions studies. HEK293 cells were cotransfected with
Myc-tagged ChREBP and HA-tagged MLX for 48 h using calcium phosphate as
above before cell lysis and nuclear extracts preparation using NucBuster
Protein Extraction Kit (Novagen) according to the manufacturer’s instruc-
tions. DNA-protein interactions were analyzed using the NoShift Transcription
Factor Assay Kit (Novagen). Brieﬂy, 5 g nuclear extracts were incubated
with a 3 biotinylated dsDNA probe and salmon sperm DNA plus Poly(dI-dC)
for 30 min on ice before transfer to a streptavidin-coated plate. Mouse
monoclonal anti-HA antibody (1/1,000) was added for1ha t37°C followed by
anti-mouse horseradish peroxidase–conjugated secondary antibody (1/1,000)
for 30 min at 37°C. 3,3,5,5-Tetramethylbenzidine substrate was added for 30
min to develop colorimetric signal before quenching with 1 N HCl. Absorbance
was read at 450 nm.
Statistical analysis. Data are given as means  SE of three to ﬁve individual
experiments. Comparisons between means were performed using two-tailed
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154 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgFIG. 1. ChREBP binds to ARNT/HIF-1 promoter in vivo in a glucose-dependent manner. A: Sequence of the mouse ARNT/HIF-1 promoter
highlighting (bold-italic) those sequences present on the Agilent chip. Underlined is the region that gave the strongest hybridization signal in the
ChIP-on-chip assay. The position of the ATG is shown in bold. B: MIN6 cells were incubated in 3 versus 30 mmol/l glucose for 16 h, as indicated
before cross-linking and chromatin immunoprecipitation using our polyclonal anti-ChREBP antibody. The primer sequences used to amplify
mouse ARNT/HIF-1 and L-PK promoters and the PCR conditions are given in RESEARCH DESIGN AND METHODS. Data are representative of three
independent experiments.
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RESULTS
ChREBP binds directly and glucose dependently to
the ARNT/HIF-1 proximal promoter in living clonal
-cells to regulate its transcription. To identify
genomic targets of ChREBP, we used an unbiased “ChIP-
on-chip” approach using high-density oligonucleotide ar-
rays (see RESEARCH DESIGN AND METHODS). The immediate 5
ﬂanking region of the ARNT/HIF-1 gene was one of the
promoter elements identiﬁed on the array as a site at
which binding of ChREBP achieved statistical conﬁdence
at P  0.1%. Given previous reports that ARNT/HIF-1
expression in islets is downregulated in type 2 diabetes in
humans and that this factor is required for the normal
regulation of insulin secretion (8), we explored the nature
and role of the ChREBP-ARNT/HIF-1 promoter interac-
tion in more detail. First, we conﬁrmed, by speciﬁc ChIP
assay, the binding of ChREBP to a region of the mouse
ARNT/HIF-1 promoter that gave the strongest signal on
the ChIP-on-chip (Fig. 1A, underlined), which was located
between 249 and 530 bp upstream of the ATG (Fig. 1B,
upper panel). Our anti-ChREBP antibody also immunopre-
cipitated a region on the mouse L-PK promoter containing
the ChoRE (23,24) and known to bind ChREBP (13,25)
(Fig. 1B, lower panel), whereas regions on the ARNT/
HIF-1 promoter located either upstream or downstream
of 530 to 249 bp area were not pulled down (Fig. 1B,
middle panels). Whereas immunoprecipitation of ChREBP
from cells incubated at 3 mmol/l glucose, and PCR ampli-
ﬁcation of this fragment, generated a relatively minor
product, a band of more than threefold greater intensity
was generated from cells incubated at elevated glucose
concentrations (30 mmol/l; Fig. 1B, upper panel). These
ﬁndings thus demonstrated that ChREBP was bound 1)
directly and 2) in a glucose-regulated manner to the
ARNT/HIF-1 promoter in living MIN6 -cells.
To further explore the roles of glucose and ChREBP in
controlling ARNT/HIF-1 gene expression, we measured
ARNT/HIF-1 mRNA levels in the highly glucose-respon-
sive -cell line, INS-1 (832/12) (20). Conﬁrming the glucose
sensitivity of ARNT/HIF-1 expression, as recently de-
scribed (26), incubation of INS-1 (832/13) cells at 20 versus
3 mmol/l glucose led to a substantial (40–50%) decrease in
the corresponding ARNT/HIF-1 mRNA levels (Fig. 2A).
These ﬁndings are consistent with the view that ChREBP
induction (27) and nuclear accumulation (13) at high
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FIG. 2. Glucose and ChREBP inhibits ARNT/HIF-1 gene expression in INS-1 (832/13) cells. A and B: INS-1 (832/13) cells were transfected for
16 h with either ChREBP-speciﬁc or -scrambled SiRNAs using TransIT-TKO and Opti-mem or (C and D) infected with ChREBP expressing or null
adenovirus at an multiplicity of infection of 100 and then incubated in 3 mmol/l glucose RPMI for 16 h followed by either 3 or 20 mmol/l glucose
RPMI as indicated for 20 h, before total RNA extraction. ARNT/HIF-1 (A and C) and ChREBP (B and D) mRNA levels were estimated by
quantitative real-time RT-PCR. The results are expressed as mean  SE of three independent experiments. *P < 0.05 for the effect of glucose.
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glucose on ARNT/HIF-1 expression. Accordingly, trans-
fection with a siRNA selective for rat ChREBP, which
decreased the corresponding mRNA levels by 	50% (Fig.
2B), resulted in a twofold increased in ARNT/HIF-1
mRNA levels at high glucose (Fig. 2A). Conversely, adeno-
viral ChREBP overexpression (supplementary Fig. 1 and
Fig. 2C in the online appendix, available at http://diabetes.
diabetesjournals.org/cgi/content/full/db08-0868/DC1) re-
sulted in signiﬁcant reduction of ARNT/HIF-1 mRNA
levels.
To further analyze the effect of ChREBP binding on
ARNT/HIF-1 gene transcription, we next generated pro-
moter-reporter luciferase constructs using fragments of
the mouse ARNT/HIF-1 promoter from 2,369 to 293
base pairs with respect to the ATG, a region of the
promoter highly conserved between species. Because
ChREBP has been shown to regulate lipogenic gene ex-
pression as a heterodimer with MLX (28), we next exam-
ined the effects of ChREBP and/or MLX overexpression on
ARNT/HIF-1 reporter activity in HEK293 cells. As shown
in Fig. 3A, overexpression of ChREBP resulted in substan-
tial inhibition of ARNT/HIF-1 promoter activity, even
without cotransfection with exogenous MLX, whereas
MLX overexpression alone activated the ARNT/HIF-1
promoter. However, as veriﬁed by qRT-PCR, MLX was
expressed in HEK293 cells [although at lower levels than
in INS-1 (832/13) cells], whereas ChREBP mRNA was
practically undetectable (not shown). To ﬁnd out whether
ChREBP binding to the ARNT/HIF-1 promoter occurs
after heterodimerization with MLX in pancreatic -cells,
we performed a ChIP assay in INS-1 (832/13) cells trans-
fected with MLX-HA, using an anti-HA antibody. As shown
in Fig. 3B, both L-PK and ARNT/HIF-1 segments of
promoter previously pulled down using anti-ChREBP an-
tibody were also immunoprecipitated using anti-HA anti-
body, whereas the region of ARNT/HIF-1 promoter
located between 1,300 and 1,001 bp was not detected.
This strongly suggests that ChREBP and MLX form a
heterodimeric complex on each promoter.
In an attempt to locate the ChREBP/MLX binding site,
truncation and deletion mutants were generated in ARNT/
HIF-1 luciferase reporter plasmid by restriction digests
(see RESEARCH DESIGN AND METHODS for details) and cotrans-
fected with either empty pcDNA3 vector or pChREBP into
HEK293 cells. As expected, and in accordance with the
ChIP-on-chip data and the ARNT/HIF-1–speciﬁc ChIP
experiment presented in Fig. 1, the deletion mutant lack-
ing the whole proximal region pulled down by ChIP was
no longer repressed by exogenous ChREBP (Fig. 4A). We
next mutated the ﬁve consensus individual E-boxes
present between 512 and 329 bp on the ARNT/HIF-1
promoter. None of these mutants, at least individually,
displayed a loss of ChREBP repression (supplemental Fig.
3A in the online appendix). Subsequently, using the
NoShift Transcription Factor Assay Kit (Novagen) as an
alternative to electrophoretic mobility shift assay, and
nuclear extracts from HEK293 cells cotransfected with
c-Myc–tagged ChREBP and HA-tagged MLX, we scanned
the ARNT/HIF-1 promoter between 519 and 220 bp,
using overlapping double-stranded DNA probes (supple-
mentary Fig. 2A). The L-PK ChoRE was used as an internal
positive control. Because only the probe located between
441 to 411 bp gave a positive signal (supplementary
Fig. 2B), we generated deletion mutants around this
region, but none of these mutants lost ChREBP repression
(supplementary Fig. 3B), suggesting that ChREBP repres-
sion of ARNT/HIF-1 promoter could demand a complex
cis element conﬁguration.
Glucose repression of ARNT/HIF-1 gene expression
requires the proximal promoter. To investigate the role
of ChREBP in mediating the glucose repression of the
ARNT/HIF-1 gene, we transfected the various ARNT
promoter-reporter luciferase constructs in INS-1 (832/13)
cells and incubated them in 3 or 20 mmol/l glucose for
24 h. Only the construct lacking the whole of the proximal
promoter (1,028 to 769 ARNT) was no longer re-
pressed by glucose; all the other mutants still showed
signiﬁcant glucose repression (Fig. 4B and data not
shown).
ChREBP overexpression inhibits ARNT/HIF-1 ex-
pression and regulates glucose-induced insulin secre-
tion from primary mouse islets. To determine whether
the observations reported above in clonal -cells were
relevant to the primary -cell, we infected isolated mouse
islets of Langerhans with ChREBP-overexpressing adeno-
virus. Whereas endogenous ChREBP mRNA levels were
FIG. 3. ChREBP represses ARNT/HIF-1 promoter activity. A: HEK293
cells were seeded in six-well plates and transfected using calcium
phosphate with 2 g pARNT-2369.LucFF, 5 ng pRL-CMV to correct for
transfection efﬁciency, and the indicated amount of plasmid encoding
transcription factors ChREBP and/or MLX. Luciferase assays were
performed 48 h later as described in RESEARCH DESIGN AND METHODS.
Results are expressed as a percentage of the ratio of Fireﬂy/Renilla
luciferase in cells with no added transcription factor, as a mean  SE
of four separate experiments. *P < 0.05 and **P < 0.005 for the effect
of added transcription factor. B: INS-1 (832/13) cells seeded in T75
ﬂasks were transfected using lipofectamine 2000 with 8 g HA-MLX
before cross-linking and chromatin immunoprecipitation using either
anti-ChREBP or anti-HA antibody as indicated. The primer sequences
to amplify the rat L-PK and ARNT/HIF-1 promoters are given under
RESEARCH DESIGN AND METHODS. Data are representative of three separate
experiments.
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mmol/l glucose, as expected, transduction of islets with
ChREBP adenovirus caused a 100-fold increase in
ChREBP mRNA levels compared with those observed at
either 3 or 17 mmol/l glucose in null adenovirus-trans-
duced islets (Fig. 5A). This forced increase in ChREBP
expression was associated with a decrease in ARNT/
HIF-1 mRNA levels at both low and high (3 and 17
mmol/l) glucose (Fig. 5B).
We have previously demonstrated that ChREBP silenc-
ing enhanced basal and glucose-stimulated insulin secre-
tion from MIN6 -cells (13). Correspondingly, we observed
here that adenovirus-mediated ChREBP overexpression in
mouse islets inhibited GSIS by 	30% (Fig. 5C).
DISCUSSION
The principal aim of the present study was to identify and
characterize new target genes that may mediate the effects
of ChREBP on -cell function. To this end, and using an
unbiased genome-wide approach, we have identiﬁed
ARNT/HIF-1 as such a target. Previously shown to be
downregulated in type 2 diabetic human islets, and to
modulate insulin secretion in the mouse (8), repression of
ARNT/HIF-1 by ChREBP represents an important poten-
tial mechanism through which the inhibitory effects of
high glucose and of ChREBP may be exerted.
Regulation of ARNT/HIF-1 by ChREBP and glucose.
ARNT/HIF-1 expression has recently been shown (26) to
be elevated at low glucose concentrations in pancreatic
MIN6 -cells. Both ARNT/HIF-1 and presenilin-1 expres-
sion were induced by low glucose, the latter being a
component of the 
-secretase complex involved in the
processing of the -amyloid precursor processing in the
brain, which may regulate -cell survival via the Notch
pathway (26). It was suggested in these earlier studies that
ARNT/HIF-1 lies downstream of presenilin in a signaling
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2 levels. The
current data support and extend these ﬁndings by demon-
strating that ARNT/HIF-1 is regulated by glucose in
primary islets as well as in clonal -cells. Moreover, the
present study also supports the view that ChREBP may
play a role that is complementary to that of presenilin-1 to
control transcription of the ARNT/HIF-1 gene as glucose
concentrations change. However, elevated glucose con-
centrations were still able to decrease ARNT/HIF-1
mRNA levels in the presence of increased, inhibitory,
ChREBP levels (Fig. 3), suggesting that multiple signaling
mechanisms may be involved in the regulation of ARNT/
HIF-1 transcription by glucose. Interestingly, in a previ-
ous report (13), we demonstrated that ChREBP binding to
the liver type (L-) pyruvate kinase gene was regulated in
part by an increase in intracellular free Ca
2 concentra-
tions. Recent studies by Scott and colleagues (29) sug-
gested that activation by glucose of the L-PK gene in
INS-1–derived 832/13 cells involves recruitment of c-Myc,
Max, and ChREBP to the promoter and a glucose-stimu-
lated increase in ChREBP transactivation. Whether the
inhibitory effects of ChREBP binding at the ARNT/HIF-1
gene promoter are similarly mediated remains to be
explored.
ChREBP has previously been shown to regulate tran-
scription of target genes both positively or negatively,
depending on the gene and context (10,12). Using ChIP,
NoShift assay, and mutational analysis, we located the
ChREBP/MLX binding site to the proximal region of
ARNT/HIF-1 promoter, a region also mediating the neg-
ative glucose effect, but the precise cis element(s) have
remained elusive. Although glucose repression of gene
expression in yeast is now well understood (30), and
involves the AMP-activated protein kinase analog Snf1
(31), our understanding of glucose inhibition of gene
expression in mammalian cells is still rudimentary. In
primary rat hepatocytes, Ma et al. (28) found 59 genes that
were repressed by high glucose, and only eight of these
were also increased by dominant-negative MLX. Whether
or not ChREBP was the interacting partner of MLX in
regulating the expression of these genes and whether
ChREBP/MLX was mediating the glucose response needs
further study.
Potential impact of ARNT/HIF-1 regulation on
-cell function. What may be the physiological conse-
quences for -cell function or survival of ChREBP-
mediated ARNT/HIF-1 repression at high glucose
concentrations? The HIF-1 complex is believed to be an
important regulator of the response to hypoxic stresses in
other cell types (32). Inhibition of ARNT/HIF-1 expres-
sion by high glucose may thus contribute to the deleteri-
ous effects on -cell mass or function during sustained
hyperglycemia observed in type 2 diabetes. This may
further exacerbate the effects of elevated nuclear levels of
ChREBP to drive lipogenic gene expression and hence,
potentially, contribute to “gluco-lipotoxicity” (1,33) under
these conditions. Correspondingly, we show here for the
ﬁrst time that ChREBP overexpression inhibits glucose-
stimulated insulin secretion from primary mouse islets by
	50%. Therapeutic approaches that may suppress
ChREBP function in islets may thus be useful for the
treatment of insulin secretory deﬁciencies in some forms
of type 2 diabetes.
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